May 06, 2016
Intercept Pharmaceuticals Inc. will fork over $55 million to resolve multidistrict litigation brought by investors accusing it of securities fraud by concealing a liver drug's side effects, according to a stipulation filed Thursday in New York federal court.
March 05, 2015
A New York federal judge on Wednesday refused to dismiss multidistrict litigation brought by investors accusing Intercept Pharmaceuticals Inc. of securities fraud, finding the investors provided evidence that the company and its executives knowingly concealed a liver drug's side effects.